GSTM1 and neoplasm: Prognostic factors in mCRPC have been examined in several clinical studies, including patient factors such as performance status (PS); hematologic factors such as hemoglobin (Hb); tumor markers such as prostate‐specific antigen (PSA), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP); and the extent of metastasis determined by imaging modalities.